Kevin King, Gregory Schiffman, James Gibson, John Quackenbush, David Liu, Bob Tepper, Anthony Simonetta, Robert Gottlieb | GenomeWeb
Gregory Schiffman has left his various senior executive positions at Affymetrix to take on the role of senior vice president and chief financial officer at Dendreon, a Seattle-based drug developer.
 
Affymetrix said last week that Schiffman resigned, effective immediately, from his posts as executive vice president, CFO, and treasurer, as well as other positions he holds at Affy subsidiaries.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.